A Study to Evaluate Whether Correction of Anemia Using Recombinant Human Erythropoietin Reduces the Progression of Atherosclerosis and Cardiac Hypertrophy in Pre-dialysis Chronic Kidney Disease Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

66 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-02-28

Study Completion Date

2003-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary aim of the study is to evaluate the effects of correction of anemia using erythropoietin on the progression of atherosclerosis and cardiac muscle thickening in patients with chronic kidney disease

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Renal Prognosis in Chronic Kidney Disease Patients With Hyporesponsive Anemia to Erythropoiesis Stimulating Agents

NCT02136563

Renal Anemia Chronic Kidney Disease

COMPLETED

Prevalence of Erythropoiesis Stimulating Agents Hyporesponsiveness in Dialysis Patients in Assiut University Hospital

NCT06053866

Erythropoietin Resistant Anemia (EPO Resistant Anemia)

NOT_YET_RECRUITING

Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal Anemia

NCT00563446

Anemia Kidney Failure, Chronic Peritoneal Dialysis, Continuous Ambulatory

COMPLETED NA

" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "

NCT06983756

Erythropoietin Resistant Anemia (EPO Resistant Anemia)

NOT_YET_RECRUITING

Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia

NCT05691257

Heart Failure Chronic Kidney Diseases Anemia

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Disease Kidney Diseases Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

erythropoietin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with chronic renal failure with serum creatinine between 150umol/L and 800umol/L and at the same time Hb
* Patients with regression line of 1/serum creatinine versus time showing that they may not require dialysis within the coming 12 months
* Patients below the age of 75

Exclusion Criteria

* Patients with valvular heart disease/congenital heart disease
* Patients with ischemic heart disease/history of myocardial infarction/coronary artery bypass surgery
* Patients with history of heart failure
* Patients with regression line of 1/serum creatinine versus time showing that the estimated date of end stage renal disease is within 12 months
* Patients with thalassemic trait or haemoglobinopathies
* Patients with underlying haematological malignancies
* Patients with active bleeding
* Patients with uncorrected iron or other vitamins deficiencies
* Patients with poor general condition

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No